GoAI
Get started
Fangzhou Inc. logo

Fangzhou Inc.

6086.HK

HKSEHealthcareMedical - Pharmaceuticals

Open in GoAI

Latest quote

HK$0.665

−HK$0.005 · -0.75%

Aug 24, 10:28 AM HKT

6086.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Headquartered in Guangzhou, China, Fangzhou Inc. delivers comprehensive online chronic disease management services throughout the nation. The company leverages its dedicated digital platform to assist individuals grappling with long-term health issues like hypertension, cardiovascular, and respiratory conditions. Its mobile application facilitates a suite of "H2H" services, comprising virtual medical consultations, e-prescribing, and prescription renewal options. Furthermore, Fangzhou provides healthcare products through an online retail pharmacy and manages its own network of hospitals and brick-and-mortar pharmacies. The company was established in 2015.

Industry
Medical - Pharmaceuticals
Sector
Healthcare
Headquarters
CN
CEO
Haijiao Wang
Listed since
Jul 9, 2024
Employees
494

Market position

Day range

Current HK$0.665

52-week range

Current HK$0.665

Open
HK$0.65
Previous close
HK$0.67
Volume
50.5K
0.08× average
Average volume
669.23K
Average daily volume
Market cap
921.32M HKD
Beta
0.86
Market reference 1
50-day average
HK$0.7582
-12.29% below average
200-day average
HK$1.7475
-61.95% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.43B CNY
P/E (TTM)
64.05×
P/B (TTM)
4.96×
P/S (TTM)
0.22×
EV / EBITDA
151.62×
Earnings yield
0.44%
Free cash flow yield
2.43%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
15.87%
Operating margin
0.38%
Net margin
0.34%
Return on equity
7.69%
Return on assets
1.45%
Return on invested capital
6.97%

Financial health

Debt / equity
0.23×
Current ratio
1.2×
Altman Z-score
2.15
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends25%5%-16%-37%Gross margin, FY2021: 14.94%Gross margin, FY2022: 20.02%Gross margin, FY2023: 20.02%Gross margin, FY2024: 19.06%Gross margin, FY2025: 15.87%Operating margin, FY2021: -11.14%Operating margin, FY2022: -11.86%Operating margin, FY2023: -2.13%Operating margin, FY2024: -28.73%Operating margin, FY2025: 0.38%Net margin, FY2021: -17.28%Net margin, FY2022: -17.39%Net margin, FY2023: -8.08%Net margin, FY2024: -31.58%Net margin, FY2025: 0.34%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 14.94%. Gross margin FY2022 20.02%. Gross margin FY2023 20.02%. Gross margin FY2024 19.06%. Gross margin FY2025 15.87%. Operating margin FY2021 -11.14%. Operating margin FY2022 -11.86%. Operating margin FY2023 -2.13%. Operating margin FY2024 -28.73%. Operating margin FY2025 0.38%. Net margin FY2021 -17.28%. Net margin FY2022 -17.39%. Net margin FY2023 -8.08%. Net margin FY2024 -31.58%. Net margin FY2025 0.34%.

Income trends

Revenue

3.53B CNY+30.24%

Operating income

13.42M CNY+791.12M CNY

Net income

11.83M CNY+866.72M CNY
Income trends across reported periods3.96B CNY2.21B CNY459.43M CNY−1.29B CNYRevenue, FY2021: 1.76B CNYRevenue, FY2022: 2.2B CNYRevenue, FY2023: 2.43B CNYRevenue, FY2024: 2.71B CNYRevenue, FY2025: 3.53B CNYOperating income, FY2021: −195.92M CNYOperating income, FY2022: −261.51M CNYOperating income, FY2023: −51.9M CNYOperating income, FY2024: −777.69M CNYOperating income, FY2025: 13.42M CNYNet income, FY2021: −303.96M CNYNet income, FY2022: −383.3M CNYNet income, FY2023: −196.79M CNYNet income, FY2024: −854.89M CNYNet income, FY2025: 11.83M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.76B CNY. Revenue FY2022 2.2B CNY. Revenue FY2023 2.43B CNY. Revenue FY2024 2.71B CNY. Revenue FY2025 3.53B CNY. Operating income FY2021 −195.92M CNY. Operating income FY2022 −261.51M CNY. Operating income FY2023 −51.9M CNY. Operating income FY2024 −777.69M CNY. Operating income FY2025 13.42M CNY. Net income FY2021 −303.96M CNY. Net income FY2022 −383.3M CNY. Net income FY2023 −196.79M CNY. Net income FY2024 −854.89M CNY. Net income FY2025 11.83M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue3.53B CNY2.71B CNY2.43B CNY2.2B CNY1.76B CNY
Cost of goods sold2.97B CNY2.19B CNY1.95B CNY2.12B CNY1.86B CNY
Gross profit559.44M CNY515.94M CNY487.41M CNY441.2M CNY262.74M CNY
Research and development36.32M CNY41.61M CNY41.53M CNY61.78M CNY45.95M CNY
Selling, general, and administrative550.23M CNY1.27B CNY374.54M CNY507.9M CNY325.84M CNY
Operating expenses546.02M CNY1.29B CNY539.3M CNY642.09M CNY415.56M CNY
Interest expense1.4M CNY2.24M CNY1.64M CNY1.17M CNY815K CNY
Depreciation and amortization3.53M CNY4.22M CNY20.32M CNY3.85M CNY2.89M CNY
Operating income13.42M CNY−777.69M CNY−51.9M CNY−261.51M CNY−195.92M CNY
Net income11.83M CNY−854.89M CNY−196.79M CNY−383.3M CNY−303.96M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.050.01-0.03-0.07Q1 '25Q3 '25Q1 '26
Q1 2025, reported Mar 21, 2025: actual -0.029, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 27, 2025: actual 0.011, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 19, 2026: actual -0.001, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates2.36B2.03B1.71B1.38BQ1 '25No estimateQ3 '25No estimateQ1 '26BeatQ3 '26Estimate
Q1 2025, reported Mar 21, 2025: actual 1.47B HKD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 27, 2025: actual 1.64B HKD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 19, 2026: actual 2.26B HKD, estimate 1.94B HKD, surprise +16.77%, Beat. Q3 2026, reported Aug 27, 2026: actual —, estimate 2.27B HKD, surprise —, Comparison unavailable.

6086.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.4

-4.08%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.30

-3.94%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$221.8

-2.72%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.54

-4.82%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.14

-5.86%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.5

-1.86%

ETFs holding 6086.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Avantis Emerging Markets Small Cap Equity ETF logoAvantis Emerging Markets Small Cap Equity ETFAVEE
Market value
1.61K
Weight
—
AUM
122.3M USD
Expense ratio
0.42%
Price / 1D
$68.1949+0.35%

Continue in GoAI

Research 6086.HK

research.disclaimer